Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BAY2927088 |
Synonyms | |
Therapy Description |
BAY2927088 is a mutant-selective EGFR inhibitor with activity against EGFR exon 20 insertions, EGFR exon 19 deletion, EGFR L858R, and EGFR C797S, which potentially results in inhibition of tumor growth (European Journal of Cancer 174 (2022): S9-S10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2927088 | BAY-2927088|BAY 2927088 | EGFR Inhibitor (Pan) 61 HER2 Inhibitor 41 | BAY2927088 is a mutant-selective EGFR inhibitor with activity against EGFR exon 20 insertions, EGFR exon 19 deletion, EGFR L858R, and EGFR C797S, which potentially results in inhibition of tumor growth (European Journal of Cancer 174 (2022): S9-S10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05099172 | Phase I | BAY2927088 | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | Recruiting | USA | NLD | ITA | FRA | ESP | BEL | 10 |